Evidence map›Paper›PMID 40265090›Full record

ArticleJournal of the National Cancer Center2025

Indoleamine 2,3-dioxygenase 1-mediated immune suppressive status is positively associated with brain metastasis in patients with non-small cell lung cancer.

Weiwei Chen, Li Yang, Victor Ho-Fun Lee, Liangliang Xu, Lingyu Ma, Zhenghao Ye, Wanli Xu, Caining Zhao, Danyang Zheng, Karrie Mei-Yee Kiang and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Cancer Center, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Weiwei ChenDepartment of Clinical Oncology, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.
Li YangDepartment of Clinical Oncology, University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Victor Ho-Fun LeeDepartment of Clinical Oncology, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.
Liangliang XuDepartment of Clinical Oncology, University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Lingyu MaDepartment of Clinical Oncology, University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Zhenghao YeDepartment of Clinical Oncology, University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Wanli XuDepartment of Clinical Oncology, University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Caining ZhaoDepartment of Clinical Oncology, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.
Danyang ZhengDepartment of Clinical Oncology, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.
Karrie Mei-Yee KiangDepartment of Surgery, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
Stella SunDepartment of Surgery, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
Yuan QuDepartment of Clinical Oncology, University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Jiandong ZhaDepartment of Clinical Oncology, University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Dazhi PangDepartment of Clinical Oncology, University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Yan ZhangDepartment of Clinical Oncology, University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Zhibing LiangDepartment of Clinical Oncology, University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Wenchu LinKey Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, China.
Jinliang ZhangDepartment of Clinical Oncology, University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Jitian ZhangDepartment of Surgery, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Min LuoDepartment of Clinical Oncology, University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Zhiyuan XuDepartment of Clinical Oncology, University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Ding LiDepartment of Pathology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Xiaoling LiangDepartment of Pathology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Gilberto Ka-Kit LeungDepartment of Surgery, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
Aya El HelaliDepartment of Clinical Oncology, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.
Chiming CheDepartment of Chemistry, State Key Laboratory of Synthetic Chemistry, The University of Hong Kong, Hong Kong, China.
Feng-Ming Spring KongDepartment of Clinical Oncology, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Indoleamine 2,3-dioxygenase (IDO1) activity, measured by kynurenine/tryptophan (K:T) ratio, is known for its association with distant metastasis and overall survival (OS) in patients with non-small cell lung cancer (NSCLC). Here, we aimed to examine whether IDO1 activity is correlated with OS in NSCLC patients with brain metastasis (Bramet) and has negative effect on modulating the anti-tumor functions of immune cells. Methods: This study was a part of a prospective clinical trial in circulating biomarkers. Blood or tissues from eligible participants were collected for measurement of kynurenine, tryptophan, immune cell subtype, scRNA-seq analysis, and untargeted metabolomics analysis. Results: A total of 195 patients were enrolled. The median kynurenine to tryptophan (K:T) ratio was 0.18, with consistent values observed among patients with NSCLC Bramet and those without (0.18 and 0.11, respectively). Notably, student's t-test analysis revealed significantly higher kynurenine concentrations in stage IV patients compared to those in stage I (2.3 vs 1.7 µM, Conclusion: IDO1 metabolites may play immune-suppressive roles in NSCLC patients with Bramet.

Indexed as

Brain metastasisImmunosuppressive biomarkerIndoleamine 2,3-dioxygenaseNon-small cell lung cancer

Identifiers

PMID40265090
PMCPMC12010389

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.